Ginkgo Bioworks Holdings, Inc. (DNA)
$
7.42
+0.63 (8.49%)
Key metrics
Financial statements
Free cash flow per share
-6.3660
Market cap
435.5 Million
Price to sales ratio
1.8344
Debt to equity
0.6712
Current ratio
4.8807
Income quality
0.5970
Average inventory
0
ROE
-0.6306
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Ginkgo Bioworks Holdings, Inc., along with its subsidiaries, specializes in developing a platform for cell programming that facilitates the biological production of various products such as novel therapeutics, food ingredients, and petroleum-derived chemicals. The company serves a diverse range of end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. As a testament to its operational performance, the company recorded an operating income of -$559,757,000.00 reflecting its earnings from core operations. The gross profit ratio is 0.83 showcasing the efficiency of the company's production and sales operations, while the gross profit stands at $188,494,000.00 highlighting its profitability from core activities. The company's stock is identified with the symbol 'DNA' in the market, and the operating income ratio is -2.47 indicating the company's operational profitability margin. Additionally, Ginkgo Bioworks has established a partnership with Selecta Biosciences, Inc. to advance the ImmTOR technology platform. Founded in 2008, the company is headquartered in Boston, Massachusetts. In the market landscape, the stock is affordable at $7.42 catering to budget-conscious investors. With a high average trading volume of 1,313,363.00 the stock indicates strong liquidity, making it an appealing option for traders. Ginkgo Bioworks, classified as a small-cap player with a market capitalization of $435,517,954.00 is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth while playing a vital role in shaping future developments in its field.
Is Ginkgo Bioworks Holdings, Inc. (DNA) a good investment?
Investing in Ginkgo Bioworks Holdings, Inc. (DNA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is Ginkgo Bioworks Holdings, Inc. (DNA)'s stock forecast?
Analysts predict Ginkgo Bioworks Holdings, Inc. stock to fluctuate between $5 (low) and $23.28 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Ginkgo Bioworks Holdings, Inc.'s market capitalization?
As of 2025-05-29, Ginkgo Bioworks Holdings, Inc.'s market cap is $435,517,954, based on 58,695,142 outstanding shares.
How does Ginkgo Bioworks Holdings, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Ginkgo Bioworks Holdings, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Ginkgo Bioworks Holdings, Inc. (DNA) stock?
To buy Ginkgo Bioworks Holdings, Inc. (DNA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for DNA. Place an order (Market, Limit, etc.).
What is the best time to invest in Ginkgo Bioworks Holdings, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Ginkgo Bioworks Holdings, Inc. stock ever split?
Ginkgo Bioworks Holdings, Inc.'s last stock split was 1:40 on 2024-08-20.
How did Ginkgo Bioworks Holdings, Inc. perform in the last earnings report?
Revenue: $227,043,000 | EPS: -$10.54 | Growth: -42.62%.
Where can I find Ginkgo Bioworks Holdings, Inc.'s investor relations reports?
Visit https://www.ginkgobioworks.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Ginkgo Bioworks Holdings, Inc.?
You can explore historical data from here
What is the all-time high and low for Ginkgo Bioworks Holdings, Inc. stock?
All-time high: $634.56 (2021-11-09) | All-time low: $5 (2025-04-04).
What are the key trends affecting Ginkgo Bioworks Holdings, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businessinsider.com
Regeneron Pharmaceuticals will acquire 23andMe's assets for $256 million, both companies said. 23andMe filed for Chapter 11 bankruptcy earlier this year.
marketwatch.com
Regeneron said it will continue uninterrupted service of 23andMe's consumer genome services — such as connecting with living relatives with shared DNA — after its purchase closes as expected in the third quarter of this year.
globenewswire.com
Company's PlaCCine® technology platform demonstrates better durability and other advantages compared to mRNA vaccines
accessnewswire.com
STONY BROOK, NY / ACCESS Newswire / May 14, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, will release its financial results for the second quarter of fiscal year 2025 (ended on March 31, 2025) after the close of the U.S. equity markets on Thursday, May 15, 2025. The Company's Form 10-Q for the period will be filed concurrently and available on the SEC Filings page of its Investor Relations website.
seekingalpha.com
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q1 2025 Results Conference Call May 6, 2025 5:00 PM ET Company Participants Daniel Marshall - Sr. Manager, Communications and Ownership Jason Kelly - Co-Founder and Chief Executive Officer Mark Dmytruk - Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Mark Massaro - BTIG Tejas Savant - Morgan Stanley Evie Koslosky - Goldman Sachs Matt Larew - William Blair Brendan Smith - TD Cowen Operator [Call Starts Abruptly] live on air. I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO.
zacks.com
Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.23. This compares to loss of $3.20 per share a year ago.
zacks.com
The latest trading day saw Ginkgo Bioworks Holdings, Inc. (DNA) settling at $7.37, representing a -0.14% change from its previous close.
zacks.com
In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $7.60, marking a +0.8% move from the previous day.
prnewswire.com
STATEN ISLAND, N.Y. , April 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new patent has been granted by the Indian Patent Office in March 2025.
accessnewswire.com
Exclusion of Canadian natural graphite from President Trump's "Liberation Day" U.S. Tariffs underscores urgency to fast-track testing and qualification with industry partners. OTTAWA, ON / ACCESS Newswire / April 9, 2025 / Focus Graphite Advanced Materials Inc. (TSXV:FMS)(OTCQB:FCSMF)(FSE:FKC) ("Focus" or the "Company"), is pleased to announce the commencement of its advanced material preparation and testing program in collaboration with U.S.-based Advanced Energy Technologies Corp. ("AETC"), a leading processor of industrial graphite and carbon materials for the upstream and advanced downstream applications.
See all news
